Blinatumomab as a bridge to trasplantation in refractory Philadelphia chromosome negative b-cell acute lymphoblastic leukemia: a case report
DOI:
https://doi.org/10.23938/ASSN.0392Keywords:
Blinatumomab. Philadelphia chromosome negative. Stem cell transplantation. Minimal residual disease. Refractory acute lymphoblastic leukemia.Abstract
Blinatumomab is a first class bispecific T-cell engager that has been shown to achieve negative minimal residual disease in patients with relapsed or refractory pre-B acute lymphoblastic leukemia after conventional chemotherapy. Nevertheless, there is little evidence about its role as an off label enhancer of cytological remission prior to stem cell transplantation (SCT).
We describe the case of a patient with an excellent performance status who was allowed to undergo alogenic SCT after a single blinatumomab cycle, as well as the management of adverse events and the observed results.
Downloads
References
WOLACH O, STONE RM. Blinatumomab for the treatment of philadelphia chromosome-negative, precursor b-cell acute lymphoblastic leukemia. Clin Cancer Res 2015; 21: 4262-4269.
TOPP MS, GÖKBUGET N, ZUGMAIER G, KLAPPERS P, STELLJES M, NEUMANN S et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014; 32: 4134-4140.
BENJAMIN JE, STEIN AS. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol 2016; 7: 142-156.
PORTELL CA, WENZELL CM, ADVANI AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acutelymphoblastic leukemia. Clin Pharmacol 2013; 12; 5: 5-11.
European Medicines Agency. Ficha técnica de Blinatumomab (Blincyto®). https://ec.europa.eu/health/documents/community-register/2015/20151123133349/anx_133349_es.pdf. Consultado el 2 de octubre de 2018.
GÖKBUGET N, DOMBRET H, BONIFACIO M, REICHLE A, GRAUX C, FAUL C et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood 2018; 22.
ZENG Y1, KATSANIS E. Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation. Bone Marrow Transplant 2017; 52: 1671-1673.
Sociedad Española de Hematología y Hemoterapia. Grupo Programa Español para el Tratamiento de las Hemopatías Malignas. Protocolo LAL-AR/2011 (versión 5 de julio de 2013) para el tratamiento de la leucemia aguda linfoblástica de alto riesgo bcr/abl negativa en adultos. https://www.sehh.es/images/stories/recursos/pethema/protocolos/LAL/LAL_AR_2011version-5-7-2013.pdf.
ZUGMAIER G, GÖKBUGET N, KLINGER M, VIARDOT A, STELLJES M, NEUMANN S et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood 2015; 126: 2578-2584.
FOLAN SA, REXWINKLE A, AUTRY J, BRYAN JC. Blinatumomab: bridging the gap in adult relapsed/refractory B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2016; 16: S2-5.
MARTINELLI G, BOISSEL N, CHEVALLIER P, OTTMANN O, GÖKBUGET N, TOPP MS et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 2017; 35: 1795-1802.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
